iShares U.S. Pharmaceuticals ETF — News

Vanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the last five years but carries higher concentration risk with only 56 holdings Vanguard Health Care ETF provides broader sector diversification by covering the entire medical ecosystem while the iShares fund focuses strictly on drug manufacturers

fool.com - 2026-07-22 16:33:01

Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a barrel. MSCI's Asia-Pacific gauge outside Japan gained 1.2%, while South Korea's Kospi surged more than 6% and Japan's Nikkei 225 climbed 1.9%.

invezz.com - 2026-07-22 00:32:10

IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.

fool.com - 2026-07-19 06:27:50

iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF

fool.com - 2026-07-18 20:16:01

The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.

fool.com - 2026-07-16 08:35:01

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.

zacks.com - 2026-07-15 07:21:07

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.

zacks.com - 2026-07-14 10:56:28

The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.

fool.com - 2026-07-10 06:41:28

The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings, while PJP spreads its bets more evenly across the sector's biggest names.

fool.com - 2026-07-05 11:16:28

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

seekingalpha.com - 2026-06-29 17:00:00

iShares U.S. Pharmaceuticals ETF offers a significantly higher dividend yield and lower volatility than State Street SPDR S&P Biotech ETF. While State Street SPDR S&P Biotech ETF delivered stronger 1-year returns, iShares U.S. Pharmaceuticals ETF showed much greater resilience with a shallower maximum drawdown.

fool.com - 2026-06-17 15:46:42

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

iShares U.S. Pharmaceuticals ETF provides more cost-efficient access to the healthcare sector with a lower expense ratio and a higher dividend yield Simplify Health Care ETF employs an active management strategy focused on innovation and donates its net profits to breast cancer research iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the past year while maintaining lower price volatility than its peer

fool.com - 2026-06-10 14:17:49

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

zacks.com - 2026-06-10 13:01:19

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

zacks.com - 2026-06-09 11:01:19

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

fool.com - 2026-05-27 11:17:39

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.

247wallst.com - 2026-05-19 16:19:54

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his ​administration's pricing deal, on Monday, a White ​House official said.

reuters.com - 2026-05-18 12:47:12

The healthcare sector is undervalued based on historical averages, especially the healthcare equipment industry. iShares U.S. Pharmaceuticals ETF offers cap-weighted exposure to U.S. pharma, with 44% in Eli Lilly and Johnson & Johnson. Recent outperformance is notable: IHE is 27% ahead of XLV over the past 12 months.

seekingalpha.com - 2026-05-16 10:42:43

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

zacks.com - 2026-05-13 11:41:07

The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

zacks.com - 2026-05-11 07:21:09

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.

zacks.com - 2026-04-29 07:21:11